Similar Papers

Paper Title
Journal
Date
Author
Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study
Robert M Rifkin ... Habte A Yimer
Blood | VOL. 134
Robert M Rifkin, et. al.Robert M Rifkin ... Habte A Yimer
13 Nov 2019
Uncovering the Blind Spot of Clinical Trials: First Report of Baseline Characteristics of Newly Diagnosed (ND) and Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients (Pts) in Insight-MM, a Global, Prospective, Observational Study
...
Blood | VOL. 130
, et. al. ...
25 Jun 2021
Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)
Peter M Voorhees ... Paul Richardson
Blood | VOL. 132
Peter M Voorhees, et. al.Peter M Voorhees ... Paul Richardson
29 Nov 2018
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial
Abhishek Maiti ...
Blood | VOL. 134
Abhishek Maiti, et. al.Abhishek Maiti ...
13 Nov 2019
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Brentuximab vedotin and nivolumab for cHL
-
Blood | VOL. 145
--
16 Jan 2025
B-1 B cells lose self-control in SCD
David R Gibb ... Sean R Stowell
Blood | VOL. 145
David R Gibb, et. al.David R Gibb ... Sean R Stowell
16 Jan 2025
Is it time to screen for multiple myeloma?
Irene M Ghobrial ... Floris Chabrun
Blood | VOL. 145
Irene M Ghobrial, et. al.Irene M Ghobrial ... Floris Chabrun
16 Jan 2025
Daratumumab for maintenance in myeloma
Cyrille Touzeau ... Aurore Perrot
Blood | VOL. 145
Cyrille Touzeau, et. al.Cyrille Touzeau ... Aurore Perrot
16 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.